首页 | 本学科首页   官方微博 | 高级检索  
检索        

三肽化合物酪丝亮肽(YSL)对腹水型肝癌H_(22)小鼠免疫调节作用实验研究
引用本文:姚智,陆融,王莉,李会强,郑敏娜,王犁明,周春雷,杨静,赵琳,高文远.三肽化合物酪丝亮肽(YSL)对腹水型肝癌H_(22)小鼠免疫调节作用实验研究[J].中国药理学通报,2006,22(10):1172-1175.
作者姓名:姚智  陆融  王莉  李会强  郑敏娜  王犁明  周春雷  杨静  赵琳  高文远
作者单位:1. 天津大学生物药学院,天津,300072;天津医科大学免疫学教研室,天津,300070
2. 天津医科大学免疫学教研室,天津,300070;深圳康哲药业有限公司,广东,深圳,518029
3. 天津医科大学免疫学教研室,天津,300070
4. 天津大学生物药学院,天津,300072
基金项目:国家高技术研究发展计划(863计划);国家重点基础研究发展计划(973计划);教育部科学技术研究重点项目
摘    要:目的观察三肽化合物酪丝亮肽(tyroserleutide,YSL)对腹水型肝癌H22小鼠的抗肿瘤作用,观察YSL对荷瘤小鼠T淋巴细胞转化及NK细胞杀伤活性的影响。方法建立腹水型肝癌H22小鼠动物模型,观察YSL对腹水型肝癌H22小鼠生存时间的影响;以MTT法检测YSL对荷瘤小鼠T淋巴细胞转化及NK细胞杀伤活性的影响。结果YSL能够明显延长腹水型肝癌H22小鼠生存时间;YSL在5μg.kg-1和50μg.kg-1时可以促进腹水型肝癌H22小鼠T淋巴细胞的转化;YSL在0.5、5和50μg.kg-1时增强荷瘤小鼠NK细胞杀伤活性。结论YSL可以延长腹水型肝癌H22小鼠的生存时间;促进荷瘤鼠的T淋巴细胞转化及NK细胞杀伤活性。

关 键 词:酪丝亮肽(YSL)  腹水型肝癌H22模型  生存时间  抗肿瘤作用
文章编号:1001-1978(2006)10-1172-04
收稿时间:2006-04-03
修稿时间:2006-04-032006-07-16

Immunological regulation of tripeptide tyroserleutide (YSL) on mice bearing ascitic fluid-type hepatocarcinoma H22
YAO Zhi,LU Rong,WANG Li,LI Hui-qiang,ZHENG Min-na,WANG Li-ming,ZHOU Chun-lei,YANG Jing,ZHAO Lin,GAO Wen-yuan.Immunological regulation of tripeptide tyroserleutide (YSL) on mice bearing ascitic fluid-type hepatocarcinoma H22[J].Chinese Pharmacological Bulletin,2006,22(10):1172-1175.
Authors:YAO Zhi  LU Rong  WANG Li  LI Hui-qiang  ZHENG Min-na  WANG Li-ming  ZHOU Chun-lei  YANG Jing  ZHAO Lin  GAO Wen-yuan
Abstract:Aim This study aimed to observe effects of tyroserleutide(tyrosyl-seryl-leucine,YSL) on the survival time of mice transplanted with the ascitic fluid-type hepatocarcinoma H_(22),as well as the T lymphocyte transformation and killing activity of NK cell impacted by YSL on mice bearing H_(22) tumor.Methods The model of ascetic fluid-type hepatocarcinoma H_(22) was established and the survival time of mice bearing H_(22) tumor treated by YSL was observed.MTT was used to observe the effect of lymphocyte transformation and killing activity of NK cells activated by YSL in vitro.Results YSL could significantly prolong the survival time of mice bearing ascetic fluid-type hepatocarcinoma H_(22).At doses of 5 and 50 μg·kg~(1),YSL could advance the T lymphocyte transformation.At doses of 0.5,5 and 50 μg·kg~(-1),YSL could enhance the killing activity of NK cells on mice bearing H_(22) tumor.Conclusion YSL can significantly prolong the survival time of mice bearing fluid-type hepatocarcinoma H_(22) and promote the effect of T lymphocyte transformation and NK cell killing activity.
Keywords:tripeptide tyroserleutide(YSL)  ascitic fluid-type hepatocarcinoma H_(22) model  survival time  anti-tumor effect
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号